Corporate Board Profile
Tech Score: 33/100
1 mention(s) identify DR. LISA C. EGBUONU-DAVIS as having software/technology expertise.
| Company | Filing Date | Evidence | Reason |
|---|---|---|---|
| OMEGA HEALTHCARE INVESTORS INC | 2024-04-23 | In 2023, she joined the Board of Phreesia, Inc. (NYSE: PHR), a publicly traded medical software company focusing on patient intake, payment processing and patient activation. | Dr. Egbuonu-Davis has experience with medical software companies and diagnostic medical devices, indicating familiarity with software and technology relevant to programming skills. |
| Filing Date | Source Excerpt |
|---|---|
| 2022-04-19 | Dr. Egbuonu-Davis brings to the Board broad strategic and operational experience in pharmaceuticals, public health and consulting, including expertise in developing and implementing research, commercialization, and investment strategies for a variety of patient populations in addition to her medical and public health expertise. |
| 2023-04-21 | Since 2019, Dr. Egbuonu-Davis has served as Vice President, Medical Innovations for DH Diagnostics, LLC, an affiliate of Danaher Corporation, where she provides medical advice to influence research, partnership and investment strategy across Danaher’s diagnostic platform businesses. Also, during this period, she has served at various times as Interim Chief Medical Officer for certain subsidiaries of Danaher Corporation. |
| 2024-04-23 | In 2023, she joined the Board of Phreesia, Inc. (NYSE: PHR), a publicly traded medical software company focusing on patient intake, payment processing and patient activation. |
Data sourced from SEC filings. Last updated: 2025-10-12